Identification
NameSalbutamol
Accession NumberDB01001  (APRD00553)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Structure
Thumb
Synonyms
Albuterol
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Salbutamol sulfate021SEF3731 51022-70-9BNPSSFBOAGDEEL-UHFFFAOYNA-NDetails
Salbutamol tartrateADS4I3E22M 661464-94-4VNVNZKCCDVFGAP-FPDJQMMJSA-NDetails
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AiromirAerosol, metered100 mcgRespiratory (inhalation)Valeant Canada Lp Valeant Canada S.E.C.1998-08-13Not applicableCanada
Albuterol SulfateSyrup2 mg/5mLOralVista Pharm, Inc.2016-09-07Not applicableUs
Albuterol SulfateSolution.75 mg/3mLRespiratory (inhalation)Mylan Pharmaceuticals2009-10-30Not applicableUs
Albuterol SulfateSolution1.5 mg/3mLRespiratory (inhalation)Mylan Pharmaceuticals2009-10-30Not applicableUs
Asmavent Nebules P.F.Liquid2.5 mgRespiratory (inhalation)Technilab Pharma Inc.1997-06-272001-09-05Canada
Asmavent Respirator Solution Inh 5mg/mlSolution5 mgRespiratory (inhalation)Technilab Pharma Inc.1993-12-312005-08-05Canada
Bci Salbutamol Inhalation SolutionSolution1 mgRespiratory (inhalation)Baker Cummins Inc2005-07-042006-10-03Canada
Bci Salbutamol Inhalation SolutionSolution2 mgRespiratory (inhalation)Baker Cummins IncNot applicableNot applicableCanada
Dom-salbutamol Respirator Solution-1mg/mlSolution1 mgRespiratory (inhalation)Dominion Pharmacal1997-05-16Not applicableCanada
Levalbuterol HydrochlorideSolution1.25 mg/3mLRespiratory (inhalation)The Ritedose Corporation2012-12-01Not applicableUs
Levalbuterol HydrochlorideSolution1.25 mg/3mLRespiratory (inhalation)Prasco, Laboratories2012-08-20Not applicableUs
Levalbuterol HydrochlorideSolution1.25 mg/3mLRespiratory (inhalation)Watson Pharmaceuticals2012-08-202015-12-29Us
Levalbuterol HydrochlorideSolution.31 mg/3mLRespiratory (inhalation)Watson Pharmaceuticals2012-08-202015-12-29Us
Levalbuterol HydrochlorideSolution.31 mg/3mLRespiratory (inhalation)Prasco, Laboratories2012-08-20Not applicableUs
Levalbuterol HydrochlorideSolution.63 mg/3mLRespiratory (inhalation)The Ritedose Corporation2012-12-01Not applicableUs
Levalbuterol HydrochlorideSolution.63 mg/3mLRespiratory (inhalation)Watson Pharmaceuticals2012-08-202015-12-29Us
Levalbuterol HydrochlorideSolution.63 mg/3mLRespiratory (inhalation)Prasco, Laboratories2012-08-20Not applicableUs
Levalbuterol Tartrate HFA InhalationAerosol, metered45 ug/1OralPreferreed Pharmaceuticals Inc.2016-12-06Not applicableUs
Levalbuterol Tartrate HFA InhalationAerosol, metered45 ug/1OralActavis Pharma Company2016-10-01Not applicableUs
Med Salbutamol Inhalation Solution 1mg/mlSolution1 mgRespiratory (inhalation)Medican Pharma Incorporated1994-12-312011-03-29Canada
Mylan-salbutamol Respirator SolutionSolution5 mgRespiratory (inhalation)Mylan Pharmaceuticals1997-11-262012-10-19Canada
Novo-salbutamol HFAAerosol, metered100 mcgRespiratory (inhalation)Teva2009-12-31Not applicableCanada
Novo-salmol Inhaler 100mcg/aemAerosol, metered100 mcgOralNovopharm Limited1991-12-312005-08-10Canada
Novo-salmol Tab 2mgTablet2 mgOralNovopharm Limited1984-12-312005-08-10Canada
Novo-salmol Tab 4mgTablet4 mgOralNovopharm Limited1984-12-312005-08-10Canada
Nu-salbutamol - Tab 2mgTablet2 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Nu-salbutamol - Tab 4mgTablet4 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Nu-salbutamol Plastic Ampules 2 mg/mlSolution2 mgRespiratory (inhalation)Nu Pharm Inc1997-12-032012-09-04Canada
Nu-salbutamol Plastic Ampules 1 mg/mlSolution1 mgRespiratory (inhalation)Nu Pharm Inc1997-12-032012-09-04Canada
PHL-salbutamol Oral LiquidSolution0.4 mgOralPharmel Inc2004-12-092016-10-25Canada
PHL-salbutamol Respirator SolutionSolution0.5 mgRespiratory (inhalation)Pharmel Inc1998-02-16Not applicableCanada
PHL-salbutamol Respirator SolutionSolution5 mgOral; Respiratory (inhalation)Pharmel IncNot applicableNot applicableCanada
PHL-salbutamol Respirator SolutionSolution1 mgRespiratory (inhalation)Pharmel Inc1998-02-16Not applicableCanada
PHL-salbutamol Respirator SolutionSolution2 mgRespiratory (inhalation)Pharmel Inc1998-02-16Not applicableCanada
PMS-salbutamolSolution5 mgOral; Respiratory (inhalation)Pharmascience Inc1994-12-31Not applicableCanada
PMS-salbutamolSolution2 mgRespiratory (inhalation)Pharmascience Inc1996-12-31Not applicableCanada
PMS-salbutamolSolution1 mgRespiratory (inhalation)Pharmascience Inc1996-12-31Not applicableCanada
PMS-salbutamolSolution0.5 mgRespiratory (inhalation)Pharmascience Inc1996-12-31Not applicableCanada
PMS-salbutamol Oral LiquidSolution0.4 mgOralPharmascience Inc2003-05-28Not applicableCanada
Proair HFAAerosol, metered90 ug/1Respiratory (inhalation)TYA Pharmaceuticals2012-12-03Not applicableUs
Proair HFAAerosol, metered90 ug/1Respiratory (inhalation)Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-21Not applicableUs
Proair HFAAerosol, metered90 ug/1Respiratory (inhalation)A S Medication Solutions2012-12-032017-06-20Us
Proair HFAAerosol, metered90 ug/1Respiratory (inhalation)Preferreed Pharmaceuticals Inc.2012-02-13Not applicableUs
Proair HFAAerosol, metered90 ug/1Respiratory (inhalation)Rebel Distributors1981-01-01Not applicableUs
Proair HFAAerosol, metered90 ug/1Respiratory (inhalation)Remedy Repack2017-02-21Not applicableUs
Proair HFAAerosol, metered90 ug/1Respiratory (inhalation)Proficient Rx LP2012-12-03Not applicableUs
Proair HFAAerosol, metered90 ug/1Respiratory (inhalation)Teva Respiratory, LLC2012-12-03Not applicableUs
Proair RespiclickPowder, metered90 ug/1Respiratory (inhalation)Teva Respiratory, LLC2015-04-23Not applicableUs
Proairhfa HFAAerosol, metered90 ug/1Respiratory (inhalation)Remedy Repack2013-06-132016-11-10Us
Proairhfa HFAAerosol, metered90 ug/1Respiratory (inhalation)H.J. Harkins Company2004-12-01Not applicableUs
Proairhfa HFAAerosol, metered90 ug/1Respiratory (inhalation)Remedy Repack2013-06-042017-02-18Us
Proventil HFAAerosol, metered108 ug/1Respiratory (inhalation)Rebel Distributors2001-10-01Not applicableUs
Proventil HFAAerosol, metered108 ug/1Respiratory (inhalation)Physicians Total Care, Inc.2009-07-17Not applicableUs
Proventil HFAAerosol, metered108 ug/1Respiratory (inhalation)Merck Sharp & Dohme Limited2001-10-01Not applicableUs
Proventil HFAAerosol, metered108 ug/1Respiratory (inhalation)Lake Erie Medical Dba Quality Care Produts Llc2001-10-01Not applicableUs
Proventil HFAAerosol, metered108 ug/1Respiratory (inhalation)A S Medication Solutions2001-10-012017-06-20Us
Ratio-salbutamolSolution5 mgRespiratory (inhalation)Teva1989-12-31Not applicableCanada
Ratio-salbutamolSolution0.5 mgRespiratory (inhalation)Teva2000-02-29Not applicableCanada
Ratio-salbutamolSolution2 mgRespiratory (inhalation)Teva2000-02-29Not applicableCanada
Ratio-salbutamolAerosol, metered100 mcgRespiratory (inhalation)Ratiopharm Inc Division Of Teva Canada Limited1989-12-312009-07-17Canada
Ratio-salbutamolSolution1 mgRespiratory (inhalation)Teva1993-12-31Not applicableCanada
Ratio-salbutamol HFAAerosol, metered100 mcgRespiratory (inhalation)Ratiopharm Inc Division Of Teva Canada Limited2001-11-092010-08-02Canada
Sabulin Inhaler 100mcg/metered Dose AerosolAerosol, metered100 mcgRespiratory (inhalation)Genpharm Ulc1989-12-312004-07-30Canada
Salbu-2 - Tab 2mgTablet2 mgOralPro Doc Limitee1996-12-312003-07-31Canada
Salbu-4 - Tab 4mgTablet4 mgOralPro Doc Limitee1996-12-062003-07-31Canada
Salbutamol HFAAerosol, metered100 mcgRespiratory (inhalation)Sanis Health Inc2014-02-13Not applicableCanada
Salbutamol Inhalation SolutionSolution1 mgRespiratory (inhalation)Ivax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Salbutamol Inhalation SolutionSolution2 mgRespiratory (inhalation)Ivax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Salbutamol Inhalation Solution P.F.-1mg/mlLiquid1 mgRespiratory (inhalation)Bdh Inc.1997-07-162000-08-03Canada
Salbutamol Nebuamp 0.05%Liquid0.05 %Respiratory (inhalation)Astra Zeneca1996-10-312001-07-23Canada
Salbutamol Nebuamp 0.1%Liquid0.1 %Respiratory (inhalation)Astra Zeneca1996-10-312002-07-30Canada
Salbutamol Nebuamp 0.2%Liquid0.2 %Respiratory (inhalation)Astra Zeneca1996-10-312001-07-23Canada
Sandoz SalbutamolSolution5 mgRespiratory (inhalation)Sandoz Canada Incorporated1995-12-312017-05-25Canada
Teva-salbutamol Sterinebs P.F.Solution1 mgRespiratory (inhalation)Teva1992-12-31Not applicableCanada
Teva-salbutamol Sterinebs P.F.Solution2 mgRespiratory (inhalation)Teva1995-12-31Not applicableCanada
Ventodisk 200mcgPowder200 mcgRespiratory (inhalation)Glaxosmithkline Inc1997-06-112007-04-03Canada
Ventodisk 400mcgPowder400 mcgRespiratory (inhalation)Glaxosmithkline Inc1997-06-022007-04-03Canada
Ventodisk Pwr 200mcg/blisterPowder200 mcgRespiratory (inhalation)Glaxo Canada Inc1989-12-311998-07-30Canada
Ventodisk Pwr 400mcg/blisterPowder400 mcgRespiratory (inhalation)Glaxo Canada Inc1989-12-311998-07-30Canada
Ventolin DiskusPowder200 mcgRespiratory (inhalation)Glaxosmithkline Inc2001-01-02Not applicableCanada
Ventolin HFAAerosol, metered100 mcgRespiratory (inhalation)Glaxosmithkline Inc2001-11-22Not applicableCanada
Ventolin HFAAerosol, metered90 ug/1Respiratory (inhalation)Glaxosmithkline Inc2006-06-09Not applicableUs
Ventolin HFAAerosol, metered90 ug/1Respiratory (inhalation)A S Medication Solutions2006-06-092017-06-20Us
Ventolin HFAAerosol, metered90 ug/1Respiratory (inhalation)Remedy Repack2016-09-14Not applicableUs
Ventolin HFAAerosol, metered90 ug/1Respiratory (inhalation)A S Medication Solutions2006-06-092017-06-20Us
Ventolin HFAAerosol, metered108 ug/1Respiratory (inhalation)Stat Rx USA2006-06-09Not applicableUs
Ventolin HFAAerosol, metered90 ug/1Respiratory (inhalation)Proficient Rx LP2006-06-09Not applicableUs
Ventolin HFAAerosol, metered90 ug/1Respiratory (inhalation)Nu Care Pharmaceuticals,inc.2006-06-09Not applicableUs
Ventolin HFAAerosol, metered108 ug/1Respiratory (inhalation)H.J. Harkins Company2006-06-09Not applicableUs
Ventolin HFAAerosol, metered90 ug/1Respiratory (inhalation)A S Medication Solutions2006-06-092017-06-20Us
Ventolin HFAAerosol, metered108 ug/1Respiratory (inhalation)Dispensing Solutions, Inc.2009-07-22Not applicableUs
Ventolin HFAAerosol, metered90 ug/1Respiratory (inhalation)Unit Dose Services2006-06-09Not applicableUs
Ventolin HFAAerosol, metered108 ug/1Respiratory (inhalation)Physicians Total Care, Inc.2009-11-11Not applicableUs
Ventolin HFAAerosol, metered108 ug/1Respiratory (inhalation)Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc2006-06-09Not applicableUs
Ventolin HFAAerosol, metered90 ug/1Respiratory (inhalation)Unit Dose Services2006-06-09Not applicableUs
Ventolin HFAAerosol, metered90 ug/1Respiratory (inhalation)Preferreed Pharmaceuticals Inc.2013-10-10Not applicableUs
Ventolin HFAAerosol, metered90 ug/1Respiratory (inhalation)Clinical Solutions Wholsesale2006-06-092017-06-24Us
Ventolin I.M. Injection 0.5mg Salbutamol In 1 Ml (500mcg/ml)Solution0.5 mgIntramuscularGlaxosmithkline Inc2000-05-022007-04-19Canada
Ventolin I.V. Bolus Injection 0.25mg Salbutamol In 5ml (50mcg/ml)Solution0.25 mgIntravenousGlaxosmithkline Inc1999-09-282002-01-29Canada
Ventolin I.V. Infusion Solution 5.0mg Salbutamol In 5ml (1000mcg/ml)Solution1 mgIntravenousGlaxosmithkline Inc1999-05-24Not applicableCanada
Ventolin Im Inj 0.5mg/mlLiquid.5 mgIntramuscularGlaxo Canada Inc1992-12-312000-08-02Canada
Ventolin InhalerAerosol, metered100 mcgRespiratory (inhalation)Glaxosmithkline Inc1997-09-302003-01-22Canada
Ventolin Inhaler 100mcg/aemAerosol, metered100 mcgRespiratory (inhalation)Glaxo Canada Inc1972-12-311998-07-30Canada
Ventolin Injection Liq IV 5mg/5mlLiquid1 mgIntravenousGlaxo Canada Inc1994-12-312000-08-02Canada
Ventolin IV Bolus Inj 0.05mg/mlLiquid.25 mgIntravenousGlaxo Canada Inc1992-12-312000-08-02Canada
Ventolin Nebules P.F. - 2.5mg/2.5mlSolution2.5 mgRespiratory (inhalation)Glaxosmithkline Inc2000-05-21Not applicableCanada
Ventolin Nebules P.F. - 5mg/2.5mlSolution5 mgRespiratory (inhalation)Glaxosmithkline Inc2000-10-02Not applicableCanada
Ventolin Nebules P.F. Liq Inh 1.25mg/2.5mlLiquid1.25 mgRespiratory (inhalation)Glaxo Canada Inc1993-12-312002-11-05Canada
Ventolin Nebules P.F. Sol 2.5mg/2.5mlLiquid2.5 mgRespiratory (inhalation)Glaxo Canada Inc1991-12-312000-08-02Canada
Ventolin Nebules P.F.- 1.25mg/2.5mlSolution1.25 mgRespiratory (inhalation)Glaxosmithkline Inc2002-06-122005-08-04Canada
Ventolin Nebules PF Sol 5mg/2.5mlLiquid5 mgRespiratory (inhalation)Glaxo Canada Inc1992-12-312001-08-01Canada
Ventolin Oral LiquidLiquid0.4 mgOralGlaxosmithkline Inc1998-12-012009-01-19Canada
Ventolin Oral Liquid 0.4mg/mlLiquid.4 mgOralGlaxo Canada Inc1993-12-311999-08-12Canada
Ventolin Respirator SolutionSolution5 mgRespiratory (inhalation)Glaxosmithkline Inc1998-12-01Not applicableCanada
Ventolin Respirator Solution 5mg/mlSolution5 mgRespiratory (inhalation)Glaxo Canada Inc1993-12-311999-08-12Canada
Ventolin RotacapsPowder200 mcgRespiratory (inhalation)Glaxosmithkline Inc1997-11-242002-01-29Canada
Ventolin RotacapsPowder400 mcgRespiratory (inhalation)Glaxosmithkline Inc1998-03-302002-01-29Canada
Ventolin Rotacaps 200mcgCapsule200 mcgRespiratory (inhalation)Glaxo Canada Inc1993-12-311998-07-30Canada
Ventolin Rotacaps 400mcgCapsule400 mcgRespiratory (inhalation)Glaxo Canada Inc1993-12-311998-07-30Canada
Ventolin Tab 4mgTablet4 mgOralGlaxo Canada Inc1993-12-311996-09-10Canada
Ventolinhfa HFAAerosol, metered108 ug/1Respiratory (inhalation)Rebel Distributors2006-06-09Not applicableUs
Ventolinhfa HFAAerosol, metered90 ug/1Respiratory (inhalation)Remedy Repack2015-08-252016-10-25Us
Ventolinhfa HFAAerosol, metered90 ug/1Respiratory (inhalation)Remedy Repack2014-01-30Not applicableUs
Ventolinhfa HFAAerosol, metered90 ug/1Respiratory (inhalation)Remedy Repack2013-06-102017-01-10Us
XopenexSolution.31 mg/3mLRespiratory (inhalation)Sunovion2002-03-012017-04-14Us
XopenexSolution1.25 mg/3mLRespiratory (inhalation)Physicians Total Care, Inc.2005-10-20Not applicableUs
XopenexSolution, concentrate1.25 mg/.5mLRespiratory (inhalation)Sunovion2004-08-012017-04-14Us
XopenexSolution1.25 mg/3mLRespiratory (inhalation)Akorn2015-02-27Not applicableUs
XopenexSolution, concentrate1.25 mg/.5mLRespiratory (inhalation)Physicians Total Care, Inc.2009-04-21Not applicableUs
XopenexSolution.63 mg/3mLRespiratory (inhalation)Sunovion1999-04-012017-04-14Us
XopenexSolution, concentrate1.25 mg/.5mLRespiratory (inhalation)Cardinal Health2004-08-01Not applicableUs
XopenexSolution.31 mg/3mLRespiratory (inhalation)Akorn2015-02-27Not applicableUs
XopenexSolution1.25 mg/3mLRespiratory (inhalation)Rebel Distributors1999-04-01Not applicableUs
XopenexSolution1.25 mg/3mLRespiratory (inhalation)Remedy Repack2016-06-092017-02-16Us
XopenexSolution.63 mg/3mLRespiratory (inhalation)Physicians Total Care, Inc.2000-12-18Not applicableUs
XopenexSolution1.25 mg/3mLRespiratory (inhalation)Sunovion1999-04-012017-04-14Us
XopenexSolution.63 mg/3mLRespiratory (inhalation)Akorn2015-02-27Not applicableUs
Xopenex HFAAerosol, metered45 ug/1OralPhysicians Total Care, Inc.2007-10-01Not applicableUs
Xopenex HFAAerosol, metered45 ug/1OralSunovion2005-12-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlbuterolTablet4 mg/1OralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs
AlbuterolTablet4 mg/1OralMylan Institutional1997-04-29Not applicableUs
AlbuterolTablet2 mg/1OralMylan Pharmaceuticals1991-01-17Not applicableUs
AlbuterolAerosol, metered90 ug/1OralRebel Distributors1996-08-14Not applicableUs
AlbuterolTablet4 mg/1OralMylan Pharmaceuticals1991-01-17Not applicableUs
AlbuterolTablet2 mg/1OralMylan Institutional1997-04-29Not applicableUs
Albuterol SulfateSyrup2 mg/5mLOralTeva1992-05-01Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)Nucare Pharmaceuticals, Inc.1997-09-17Not applicableUs
Albuterol SulfateTablet2 mg/1Oralbryant ranch prepack1989-12-05Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)Nephron Pharmaceuticals Corporation1997-09-17Not applicableUs
Albuterol SulfateSolution5 mg/mLRespiratory (inhalation)Rebel Distributors1998-01-15Not applicableUs
Albuterol SulfateTablet2 mg/1OralRemedy Repack2013-05-072017-01-20Us
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)Physicians Total Care, Inc.2003-10-21Not applicableUs
Albuterol SulfateSyrup2 mg/5mLOcclusive dressing techniqueDispensing Solutions, Inc.1998-01-30Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)Clinical Solutions Wholsesale1997-09-172017-07-01Us
Albuterol SulfateSolution2.5 mg/3mLIntrabronchialRemedy Repack2017-03-02Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)Proficient Rx LP1997-09-17Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)Aidarex Pharmaceuticals LLC2011-12-05Not applicableUs
Albuterol SulfateTablet2.4 mg/1OralPhysicians Total Care, Inc.1993-08-13Not applicableUs
Albuterol SulfateSolution1.5 mg/3mLRespiratory (inhalation)Physicians Total Care, Inc.2007-04-26Not applicableUs
Albuterol SulfateSyrup2 mg/5mLOralAtlantic Biologicals Corps.1998-01-30Not applicableUs
Albuterol SulfateTablet2 mg/1OralAvera Mc Kennan Hospital2015-09-09Not applicableUs
Albuterol SulfateTablet4 mg/1OralAmerincan Health Packaging2015-09-01Not applicableUs
Albuterol SulfateTablet, film coated, extended release4 mg/1OralMylan Pharmaceuticals2007-01-30Not applicableUs
Albuterol SulfateSolution1.25 mg/3mLIntrabronchialWatson Pharmaceuticals2007-09-25Not applicableUs
Albuterol SulfateSyrup2 mg/5mLOralLake Erie Medical Dba Quality Care Produts Llc2011-02-212017-01-24Us
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)Mylan Pharmaceuticals2012-10-15Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)Sandoz2011-08-17Not applicableUs
Albuterol SulfateSolution2 mg/5mLOralPreferreed Pharmaceuticals Inc.2012-01-102017-04-20Us
Albuterol SulfateSolution2.5 mg/3mLIntrabronchialUnit Dose Services2010-11-04Not applicableUs
Albuterol SulfateTablet2 mg/1OralPreferreed Pharmaceuticals Inc.1989-12-05Not applicableUs53489 0176 01 nlmimage10 623fb12d
Albuterol SulfateTablet4 mg/1Oralbryant ranch prepack1989-12-05Not applicableUs
Albuterol SulfateSolution5 mg/mLRespiratory (inhalation)Bauch & Lomb Incorporated1998-06-18Not applicableUs
Albuterol SulfateSyrup2 mg/5mLOralPreferreed Pharmaceuticals Inc.2016-09-26Not applicableUs
Albuterol SulfateSolution5 mg/mLRespiratory (inhalation)Hi Tech Pharmacal Co., Inc.1998-01-15Not applicableUs
Albuterol SulfateSolution2.5 mg/.5mLRespiratory (inhalation)Nephron Pharmaceuticals Corporation2001-06-26Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)Rebel Distributors1997-09-17Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)Remedy Repack2013-06-102017-02-16Us
Albuterol SulfateSyrup2 mg/5mLOralPhysicians Total Care, Inc.1994-10-13Not applicableUs
Albuterol SulfateTablet2 mg/1OralSun Pharmaceutical Industries Limited1989-12-05Not applicableUs
Albuterol SulfateSolution2.5 mg/.5mLRespiratory (inhalation)Cardinal Health2001-06-26Not applicableUs
Albuterol SulfateSyrup2 mg/5mLOralActavis Pharma Company2016-02-192016-04-21Us
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)A S Medication Solutions2011-12-052017-06-20Us
Albuterol SulfateSolution2.5 mg/3mLIntrabronchialPreferreed Pharmaceuticals Inc.2015-04-21Not applicableUs
Albuterol SulfateTablet, film coated, extended release8 mg/1OralMylan Pharmaceuticals2007-01-30Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLIntrabronchialActavis Pharma Company2010-11-04Not applicableUs
Albuterol SulfateSyrup2 mg/5mLOralHi Tech Pharmacal Co., Inc.1998-01-30Not applicableUs
Albuterol SulfateSolution.75 mg/3mLRespiratory (inhalation)Nephron Pharmaceuticals Corporation2010-03-31Not applicableUs
Albuterol SulfateTablet2 mg/1OralRemedy Repack2013-03-062017-01-25Us
Albuterol SulfateSolution2.5 mg/3mLIntrabronchialRemedy Repack2015-05-182017-04-14Us
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)The Ritedose Corporation2011-12-05Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLIntrabronchialRemedy Repack2016-06-202017-02-15Us
Albuterol SulfateSolution.83 mg/mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.1997-09-17Not applicableUs
Albuterol SulfateSolution5 mg/mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.2012-07-27Not applicableUs
Albuterol SulfateTablet4 mg/1OralSun Pharmaceutical Industries Limited1989-12-05Not applicableUs53489 0177 01 nlmimage10 db03eddf
Albuterol SulfateTablet2 mg/1OralAmerincan Health Packaging2015-09-01Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)Cardinal Health1997-09-17Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLIntrabronchialUnit Dose Services2010-11-04Not applicableUs
Albuterol SulfateSolution.63 mg/3mLIntrabronchialWatson Pharmaceuticals2007-09-25Not applicableUs
Albuterol SulfateSolution1.5 mg/3mLRespiratory (inhalation)Nephron Pharmaceuticals Corporation2004-06-28Not applicableUs
Albuterol SulfateSyrup2 mg/5mLOralRebel Distributors1998-01-30Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLIntrabronchialA S Medication Solutions2010-11-042017-06-20Us
Albuterol SulfateSolution5 mg/mLRespiratory (inhalation)Physicians Total Care, Inc.1994-10-19Not applicableUs
Albuterol SulfateSolution1.5 mg/3mLRespiratory (inhalation)Cardinal Health2004-06-28Not applicableUs
Albuterol SulfateSyrup2 mg/5mLOralPreferreed Pharmaceuticals Inc.2011-06-03Not applicableUs
Albuterol SulfateSolution5 mg/mLRespiratory (inhalation)A S Medication Solutions1998-01-152017-06-20Us
Albuterol SulfateTablet4 mg/1OralPreferreed Pharmaceuticals Inc.1989-12-05Not applicableUs
Albuterol SulfateSolution2 mg/5mLOralQualitest2006-12-272016-10-20Us
Albuterol Sulfate ERTablet, extended release4 mg/1OralDAVA Pharmaceuticals, Inc.2002-09-30Not applicableUs68774 0400 01 nlmimage10 d803ec2f
Albuterol Sulfate ERTablet, extended release8 mg/1OralDAVA Pharmaceuticals, Inc.2002-09-30Not applicableUs
Apo-salvent 5mg/mlSolution5 mgOral; Respiratory (inhalation)Apotex Corporation1994-12-31Not applicableCanada
Apo-salvent Aem 100mcgAerosol, metered100 mcgRespiratory (inhalation)Apotex Corporation1989-12-31Not applicableCanada
Apo-salvent Cfc FreeAerosol, metered100 mcgRespiratory (inhalation)Apotex Corporation2002-08-22Not applicableCanada
Apo-salvent SterulesSolution2 mgRespiratory (inhalation)Apotex Corporation1998-02-10Not applicableCanada
Apo-salvent SterulesSolution1 mgRespiratory (inhalation)Apotex Corporation1997-06-25Not applicableCanada
Apo-salvent SterulesSolution0.5 mgRespiratory (inhalation)Apotex Corporation2001-08-28Not applicableCanada
Apo-salvent Tablets - 2mgTablet2 mgOralApotex Corporation1995-12-31Not applicableCanada
Apo-salvent Tablets - 4mgTablet4 mgOralApotex Corporation1995-12-31Not applicableCanada
LevalbuterolSolution1.25 mg/3mLRespiratory (inhalation)Mylan Pharmaceuticals2013-03-15Not applicableUs
LevalbuterolSolution.63 mg/3mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.2016-10-24Not applicableUs
LevalbuterolSolution.31 mg/3mLRespiratory (inhalation)Mylan Pharmaceuticals2013-03-15Not applicableUs
LevalbuterolSolution.63 mg/3mLRespiratory (inhalation)Mylan Pharmaceuticals2013-03-15Not applicableUs
LevalbuterolSolution, concentrate1.25 mg/.5mLRespiratory (inhalation)Teva2014-12-16Not applicableUs
Levalbuterol HydrochlorideSolution.63 mg/3mLRespiratory (inhalation)Actavis Pharma Company2014-06-10Not applicableUs
Levalbuterol HydrochlorideSolution.31 mg/3mLRespiratory (inhalation)Actavis Pharma Company2014-06-10Not applicableUs
Levalbuterol HydrochlorideSolution1.25 mg/.5mLRespiratory (inhalation)Cardinal Health2009-08-28Not applicableUs
Levalbuterol HydrochlorideSolution1.25 mg/3mLRespiratory (inhalation)Actavis Pharma Company2014-06-10Not applicableUs
Levalbuterol HydrochlorideSolution1.25 mg/.5mLRespiratory (inhalation)Mylan Pharmaceuticals2009-08-28Not applicableUs
Levalbuterol InhalationSolution1.25 mg/3mLRespiratory (inhalation)Dr Reddy's Laboratories2014-09-16Not applicableUs
Levalbuterol InhalationSolution.63 mg/3mLRespiratory (inhalation)Dr Reddy's Laboratories2014-09-16Not applicableUs
Levalbuterol InhalationSolution1.25 mg/3mLRespiratory (inhalation)Remedy Repack2015-05-07Not applicableUs
Levalbuterol InhalationSolution.31 mg/3mLRespiratory (inhalation)Dr Reddy's Laboratories2014-09-16Not applicableUs
Vospire ERTablet, extended release4 mg/1OralDAVA Pharmaceuticals, Inc.2002-09-30Not applicableUs
Vospire ERTablet, extended release8 mg/1OralDAVA Pharmaceuticals, Inc.2002-09-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AccuNebNot Available
AerolinNot Available
AsmolNot Available
AsthalinNot Available
AsthaventNot Available
ProAirTeva
PROAIRHFANot Available
ProventilNot Available
SalamolNot Available
VentilanGlaxoSmithKline
VentolinGlaxoSmithKline
VentolineGlaxoSmithKline
VENTOLINHFANot Available
VentorlinGlaxoSmithKline
VoSpireNot Available
Brand mixtures
NameLabellerIngredients
Apo-salvent-ipravent SterulesApotex Corporation
Combivent Inhalation AerosolBoehringer Ingelheim (Canada) Ltd Ltee
Combivent RespimatBoehringer Ingelheim (Canada) Ltd Ltee
Combivent UdvBoehringer Ingelheim (Canada) Ltd Ltee
DuonebMylan Specialty
IpramolIvax Pharmaceuticals Incorporated
Ipratropium Bromide and Albuterol SulfateTeva
Ratio-ipra Sal UdvTeva
Teva-combo SterinebsTeva
Categories
UNIIQF8SVZ843E
CAS number18559-94-9
WeightAverage: 239.3107
Monoisotopic: 239.152143543
Chemical FormulaC13H21NO3
InChI KeyNDAUXUAQIAJITI-UHFFFAOYSA-N
InChI
InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3
IUPAC Name
4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
SMILES
CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
Pharmacology
Indication

For symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, and other chronic bronchopulmonary disorders such as COPD.

Structured Indications
Pharmacodynamics

Salbutamol (INN) or albuterol (USAN), a moderately selective beta(2)-receptor agonist similar in structure to terbutaline, is widely used as a bronchodilator to manage asthma and other chronic obstructive airway diseases. The R-isomer, levalbuterol, is responsible for bronchodilation while the S-isomer increases bronchial reactivity. The R-enantiomer is sold in its pure form as Levalbuterol. The manufacturer of levalbuterol, Sepracor, has implied (although not directly claimed) that the presence of only the R-enantiomer produces fewer side-effects.

Mechanism of action

Salbutamol is a beta(2)-adrenergic agonist and thus it stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that salbutamol increases cAMP production by activating adenylate cyclase, and the actions of salbutamol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to a smooth muscle relaxation and bronchodilation. In addition to bronchodilation, salbutamol inhibits the release of bronchoconstricting agents from mast cells, inhibits microvascular leakage, and enhances mucociliary clearance.

TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-2 adrenergic receptorProteinyes
agonist
HumanP07550 details
Beta-1 adrenergic receptorProteinunknown
agonist
HumanP08588 details
Beta-3 adrenergic receptorProteinunknownNot AvailableHumanP13945 details
Related Articles
Absorption

Systemic absorption is rapid following aerosol administration.

Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to salbutamol 4'-O-sulfate.

SubstrateEnzymesProduct
Salbutamol
Not Available
Salbutamol 4-O-sulfateDetails
Route of elimination

Approximately 72% of the inhaled dose is excreted in the urine within 24 hours, 28% as unchanged drug and 44% as metabolite.

Half life

1.6 hours

ClearanceNot Available
Toxicity

LD50=1100 mg/kg (orally in mice)

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Salbutamol.Experimental
AcebutololAcebutolol may decrease the bronchodilatory activities of Salbutamol.Approved
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Salbutamol.Approved, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Salbutamol.Approved, Withdrawn
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Salbutamol.Illicit, Withdrawn
AmiodaroneSalbutamol may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Salbutamol.Approved
AnagrelideSalbutamol may increase the QTc-prolonging activities of Anagrelide.Approved
Arsenic trioxideSalbutamol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherSalbutamol may increase the QTc-prolonging activities of Artemether.Approved
AsenapineSalbutamol may increase the QTc-prolonging activities of Asenapine.Approved
AtenololAtenolol may decrease the bronchodilatory activities of Salbutamol.Approved
AtomoxetineAtomoxetine may increase the tachycardic activities of Salbutamol.Approved
AzithromycinSalbutamol may increase the QTc-prolonging activities of Azithromycin.Approved
BedaquilineSalbutamol may increase the QTc-prolonging activities of Bedaquiline.Approved
BendroflumethiazideSalbutamol may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Salbutamol.Withdrawn
Benzylpenicilloyl PolylysineSalbutamol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Betahistine.Approved
BetaxololBetaxolol may decrease the bronchodilatory activities of Salbutamol.Approved
BisoprololBisoprolol may decrease the bronchodilatory activities of Salbutamol.Approved
BopindololBopindolol may decrease the bronchodilatory activities of Salbutamol.Approved
BromocriptineBromocriptine may increase the hypertensive activities of Salbutamol.Approved, Investigational
BucindololBucindolol may decrease the vasoconstricting activities of Salbutamol.Investigational
BumetanideSalbutamol may increase the hypokalemic activities of Bumetanide.Approved
BupranololBupranolol may decrease the bronchodilatory activities of Salbutamol.Approved
CabergolineCabergoline may increase the hypertensive activities of Salbutamol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Salbutamol.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Salbutamol.Approved
CarvedilolCarvedilol may decrease the vasoconstricting activities of Salbutamol.Approved, Investigational
CeliprololCeliprolol may decrease the bronchodilatory activities of Salbutamol.Approved, Investigational
CeritinibSalbutamol may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquineSalbutamol may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideSalbutamol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineSalbutamol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorthalidoneSalbutamol may increase the hypokalemic activities of Chlorthalidone.Approved
CiprofloxacinSalbutamol may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideSalbutamol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramSalbutamol may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinSalbutamol may increase the QTc-prolonging activities of Clarithromycin.Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Salbutamol.Approved, Vet Approved
ClozapineSalbutamol may increase the QTc-prolonging activities of Clozapine.Approved
CrizotinibSalbutamol may increase the QTc-prolonging activities of Crizotinib.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Salbutamol.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Salbutamol.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Salbutamol.Approved
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Salbutamol.Approved
DisopyramideSalbutamol may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideSalbutamol may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronSalbutamol may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneSalbutamol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Salbutamol.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Salbutamol.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Salbutamol.Approved
DronedaroneSalbutamol may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolSalbutamol may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Salbutamol.Approved
EliglustatSalbutamol may increase the QTc-prolonging activities of Eliglustat.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Salbutamol.Approved
ErgonovineErgonovine may increase the hypertensive activities of Salbutamol.Approved
ErgotamineErgotamine may increase the hypertensive activities of Salbutamol.Approved
ErythromycinSalbutamol may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramSalbutamol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Salbutamol.Investigational
EsmololEsmolol may decrease the bronchodilatory activities of Salbutamol.Approved
Etacrynic acidSalbutamol may increase the hypokalemic activities of Etacrynic acid.Approved
FlecainideSalbutamol may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluoxetineSalbutamol may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolSalbutamol may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Salbutamol.Approved, Vet Approved
FurosemideSalbutamol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Gadobenic acidSalbutamol may increase the QTc-prolonging activities of Gadobenic acid.Approved
GemifloxacinSalbutamol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GoserelinSalbutamol may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronSalbutamol may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
HaloperidolSalbutamol may increase the QTc-prolonging activities of Haloperidol.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Salbutamol.Experimental
HydrochlorothiazideSalbutamol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideSalbutamol may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbutilideSalbutamol may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneSalbutamol may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Salbutamol.Approved
IndapamideSalbutamol may increase the hypokalemic activities of Indapamide.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Salbutamol.Withdrawn
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Salbutamol.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Salbutamol.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Salbutamol.Approved
LabetalolLabetalol may decrease the vasoconstricting activities of Salbutamol.Approved
LenvatinibSalbutamol may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideSalbutamol may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinSalbutamol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Salbutamol.Approved
LopinavirSalbutamol may increase the QTc-prolonging activities of Lopinavir.Approved
LoxapineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Loxapine.Approved
LumefantrineSalbutamol may increase the QTc-prolonging activities of Lumefantrine.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Salbutamol.Withdrawn
MethadoneSalbutamol may increase the QTc-prolonging activities of Methadone.Approved
MethyclothiazideSalbutamol may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Salbutamol.Investigational
MetolazoneSalbutamol may increase the hypokalemic activities of Metolazone.Approved
MetoprololMetoprolol may decrease the bronchodilatory activities of Salbutamol.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Salbutamol.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Salbutamol.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Salbutamol.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Salbutamol.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Salbutamol.Approved
MoxifloxacinSalbutamol may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NadololNadolol may decrease the bronchodilatory activities of Salbutamol.Approved
NebivololNebivolol may decrease the bronchodilatory activities of Salbutamol.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Salbutamol.Withdrawn
NilotinibSalbutamol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Salbutamol.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Salbutamol.Withdrawn
OfloxacinSalbutamol may increase the QTc-prolonging activities of Ofloxacin.Approved
OndansetronSalbutamol may increase the QTc-prolonging activities of Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Salbutamol.Investigational
OxprenololOxprenolol may decrease the bronchodilatory activities of Salbutamol.Approved
PaliperidoneSalbutamol may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatSalbutamol may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Salbutamol.Approved
PazopanibSalbutamol may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Salbutamol.Approved, Investigational
PentamidineSalbutamol may increase the QTc-prolonging activities of Pentamidine.Approved
PerflutrenSalbutamol may increase the QTc-prolonging activities of Perflutren.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Salbutamol.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Salbutamol.Withdrawn
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Salbutamol.Withdrawn
PimozideSalbutamol may increase the QTc-prolonging activities of Pimozide.Approved
PindololPindolol may decrease the bronchodilatory activities of Salbutamol.Approved
PiretanideSalbutamol may increase the hypokalemic activities of Piretanide.Experimental
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Salbutamol.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Salbutamol.Withdrawn
PolythiazideSalbutamol may increase the hypokalemic activities of Polythiazide.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Salbutamol.Approved
PrimaquineSalbutamol may increase the QTc-prolonging activities of Primaquine.Approved
ProcainamideSalbutamol may increase the QTc-prolonging activities of Procainamide.Approved
PromazineSalbutamol may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenoneSalbutamol may increase the QTc-prolonging activities of Propafenone.Approved
PropranololPropranolol may decrease the bronchodilatory activities of Salbutamol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Salbutamol.Approved
QuetiapineSalbutamol may increase the QTc-prolonging activities of Quetiapine.Approved
QuinethazoneSalbutamol may increase the hypokalemic activities of Quinethazone.Approved
QuinidineSalbutamol may increase the QTc-prolonging activities of Quinidine.Approved
QuinineSalbutamol may increase the QTc-prolonging activities of Quinine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Salbutamol.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Salbutamol.Withdrawn
SaquinavirSalbutamol may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Salbutamol.Approved, Investigational, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Salbutamol.Approved
SotalolSotalol may decrease the bronchodilatory activities of Salbutamol.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Salbutamol.Approved
SulfisoxazoleSalbutamol may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
TamsulosinTamsulosin may decrease the vasoconstricting activities of Salbutamol.Approved, Investigational
TelavancinSalbutamol may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinSalbutamol may increase the QTc-prolonging activities of Telithromycin.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Salbutamol.Approved
TetrabenazineSalbutamol may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineSalbutamol may increase the QTc-prolonging activities of Thioridazine.Withdrawn
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Salbutamol.Approved
TimololTimolol may decrease the bronchodilatory activities of Salbutamol.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Salbutamol.Approved
TorasemideSalbutamol may increase the hypokalemic activities of Torasemide.Approved
ToremifeneSalbutamol may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Salbutamol.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salbutamol.Approved
TrichlormethiazideSalbutamol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Salbutamol.Experimental
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Salbutamol.Approved
VandetanibSalbutamol may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibSalbutamol may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Salbutamol.Approved
ZiprasidoneSalbutamol may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolSalbutamol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Toshikuni Kawazi, Masahiro Ono, Nobuko Inoue, "Salbutamol-containing plaster and method of producing same." U.S. Patent US5068103, issued February, 1984.

US5068103
General ReferencesNot Available
External Links
ATC CodesR03AL02 — Salbutamol and ipratropium bromideR03AK04 — Salbutamol and sodium cromoglicateR03CC02 — SalbutamolR03AC02 — Salbutamol
AHFS Codes
  • 12:12.08.12
  • 48:12.04.12
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (52.5 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers3
1CompletedBasic SciencePulmonary Disease, Chronic Obstructive1
1CompletedDiagnosticAirway Inflammation1
1CompletedDiagnosticPulmonary Disease, Chronic Obstructive1
1CompletedDiagnosticSickle Cell Disorders1
1CompletedTreatmentAsthma Bronchial1
1CompletedTreatmentAsthma Bronchial / Diabetes Mellitus (DM)1
1CompletedTreatmentAsthma, Allergic1
1CompletedTreatmentCongenital Myasthenic Syndrome1
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentPompe's Disease1
1RecruitingBasic ScienceCardiovascular System Disease / Drug-Related Side Effects and Adverse Reactions1
1RecruitingTreatmentStatus Asthmaticus1
1, 2CompletedTreatmentPompe's Disease1
2CompletedBasic ScienceMemory Functions1
2CompletedDiagnosticLung Diseases, Obstructive1
2CompletedTreatmentAsthma Bronchial12
2CompletedTreatmentAsthma Bronchial / Bronchospasm1
2CompletedTreatmentAsthma Bronchial / Efficacy / Safety1
2CompletedTreatmentBrain Death / Organ Donors / Pulmonary Edemas1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2CompletedTreatmentChronic Respiratory Failure / Clinically Significant Increase in Maximum Expiratory Volume Per Second1
2CompletedTreatmentPulmonary Disease, Chronic Obstructive2
2RecruitingTreatmentAsthma Bronchial1
2RecruitingTreatmentLymphangioleiomyomatosis1
2Unknown StatusTreatmentAsthma Bronchial1
2WithdrawnTreatmentIdiopathic Pulmonary Arterial Hypertension1
2, 3CompletedTreatmentAllergies1
2, 3TerminatedTreatmentRespiratory Distress Syndrome, Adult1
2, 3WithdrawnTreatmentCongestive Heart Failure (CHF)1
3CompletedTreatmentAllergies / Conjunctivitis / Rhinitis / Rhinoconjunctivitis2
3CompletedTreatmentAsthma Bronchial18
3CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentBronchial Asthma2
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)7
3CompletedTreatmentOrganophosphate Poisoning1
3CompletedTreatmentPersistent Asthma1
3CompletedTreatmentPulmonary Disease, Chronic Obstructive5
3CompletedTreatmentReactive Airways Disease (RAD)1
3RecruitingTreatmentAsthma Bronchial3
3RecruitingTreatmentBronchial Asthma1
3RecruitingTreatmentCongestive Heart Failure (CHF) / Heart Failure, Left-Sided / Left-Sided Heart Failure1
3RecruitingTreatmentRhinitis, Allergic, Seasonal1
3TerminatedPreventionAsthma Bronchial / Bronchospasm1
3TerminatedTreatmentAsthma Bronchial1
3Unknown StatusTreatmentPulmonary Disease, Chronic Obstructive1
3WithdrawnTreatmentAsthma Bronchial1
3WithdrawnTreatmentAsthma Bronchial / Chronic Lung Diseases1
3WithdrawnTreatmentPulmonary Disease, Chronic Obstructive1
4Active Not RecruitingTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD) / Healthy Volunteers1
4Active Not RecruitingTreatmentPulmonary Disease, Chronic Obstructive1
4CompletedNot AvailableAsthma Bronchial2
4CompletedBasic ScienceAsthma Bronchial1
4CompletedBasic ScienceBronchoconstriction / Cycling Performance / Exercise-Induced Bronchoconstriction (EIB) / Inhaled Salbutamol1
4CompletedDiagnosticAsthma Bronchial1
4CompletedDiagnosticObliterative Bronchiolitis1
4CompletedHealth Services ResearchAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
4CompletedPreventionAsthma Bronchial / Heart Rate Fast1
4CompletedSupportive CareAsthma Bronchial1
4CompletedSupportive CareChronic Obstructive Pulmonary Disease (COPD) / Sepsis / Shock1
4CompletedTreatmentAcute Asthma / Asthma Bronchial / Reactive Airway Exacerbation1
4CompletedTreatmentAsthma Bronchial9
4CompletedTreatmentChildhood Asthma1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)2
4CompletedTreatmentPompe's Disease1
4CompletedTreatmentPulmonary Disease, Chronic Obstructive3
4Not Yet RecruitingTreatmentVentricular Septal Defects1
4RecruitingNot AvailableAsthma Bronchial / Food Allergy / Obstructive Sleep Apnea (OSA) / Viruses / Wheezing1
4RecruitingTreatmentAir Trapping / Airflow Limitation / Hyperinflation / Obstructive Lung Diseases / Secondhand Smoke / Tobacco1
4RecruitingTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentAsthmatic Bronchitis / Obstruction Airway / Wheezing / Wheezy Bronchitis1
4TerminatedTreatmentAcute Asthma1
4TerminatedTreatmentAsthma Bronchial1
4TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4Unknown StatusDiagnosticChronic Lung Disease of Prematurity / Very Low Birth Weight1
4Unknown StatusPreventionCesarean Section / Postnatal Pulmonary Adaptation1
4Unknown StatusTreatmentAsthma Bronchial1
4Unknown StatusTreatmentBronchial Asthma1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4WithdrawnTreatmentAsthma Bronchial1
4WithdrawnTreatmentWheezing1
Not AvailableActive Not RecruitingBasic ScienceAdrenergic Beta-2 Agonist Effect / Adrenergic Beta-2 Agonist Effect in Healthy Subjects / Albuterol Effect / Albuterol Effect in Healthy Subjects1
Not AvailableCompletedNot AvailableAsthma Bronchial / Chronic Bronchitis / Chronic Obstructive Pulmonary Disease (COPD) / Emphysema1
Not AvailableCompletedBasic ScienceCystic Fibrosis (CF) / Healthy Volunteers1
Not AvailableCompletedBasic ScienceMuscle Hypertrophy in Healthy Young Men1
Not AvailableCompletedDiagnosticAsthma Bronchial1
Not AvailableCompletedDiagnosticBronchodilation1
Not AvailableCompletedDiagnosticChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedDiagnosticHematopoietic Stem Cell Transplantation (HSCT) / Obliterative Bronchiolitis1
Not AvailableCompletedHealth Services ResearchAsthma Bronchial1
Not AvailableCompletedHealth Services ResearchChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedTreatmentAsthma Bronchial2
Not AvailableCompletedTreatmentAsthma Bronchial / Children1
Not AvailableCompletedTreatmentAsthma Placebo Effects1
Not AvailableCompletedTreatmentAutoimmune Diseases / Disseminated Sclerosis1
Not AvailableCompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedTreatmentModerate and Severe Acute Asthma Exacerbations in Pediatric Patients1
Not AvailableCompletedTreatmentMuscular Dystrophy1
Not AvailableCompletedTreatmentMuscular Dystrophy, Facioscapulohumeral1
Not AvailableCompletedTreatmentPneumonia1
Not AvailableCompletedTreatmentRespiratory Failure1
Not AvailableEnrolling by InvitationBasic ScienceOxygen Consumption1
Not AvailableNot Yet RecruitingDiagnosticChildhood Asthma1
Not AvailableNot Yet RecruitingTreatmentHigh Flow Nasal Cannula1
Not AvailableRecruitingNot AvailableAAT Deficiency / AATD / Alpha-1 Antitrypsin Deficiency / Cystic Fibrosis (CF)1
Not AvailableRecruitingNot AvailableAirway Disease Small / Hypersensitivity Pneumonitis1
Not AvailableRecruitingNot AvailableAortic Valve Stenosis / Hypertension,Essential / Impaired Renal Function / Secondary Hypertension1
Not AvailableRecruitingHealth Services ResearchAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableRecruitingTreatmentAsthma Bronchial2
Not AvailableRecruitingTreatmentRespiratory Muscle Weakness / Spinal Cord Injuries (SCI)1
Not AvailableRecruitingTreatmentSevere Bronchopulmonary Dysplasia1
Not AvailableSuspendedTreatmentCystic Fibrosis (CF)1
Not AvailableTerminatedBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableUnknown StatusNot AvailableAsthma Bronchial1
Not AvailableUnknown StatusNot AvailableChronic Obstructive Pulmonary Disease (COPD) / Emphysema1
Not AvailableUnknown StatusNot AvailableElectrophysiological Parameters / Influence of Nebulized Bronchodilatators on Selected1
Not AvailableUnknown StatusNot AvailableErgogenic Effects of Salbutamol in Healthy Males1
Not AvailableUnknown StatusDiagnosticTuberculosis1
Not AvailableUnknown StatusTreatmentAsthma Bronchial1
Not AvailableUnknown StatusTreatmentBronchiolitis1
Not AvailableUnknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)2
Not AvailableUnknown StatusTreatmentHeart Failure, Unspecified / Ischaemic Cardiomyopathy / Non-ischaemic Cardiomyopathy1
Pharmacoeconomics
Manufacturers
  • Armstrong pharmaceuticals inc
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Pliva inc
  • Schering corp sub schering plough corp
  • Glaxosmithkline
  • Teva global respiratory research llc
  • 3m pharmaceuticals inc
  • Dey lp
  • Actavis mid atlantic llc
  • Apotex inc richmond hill
  • Apotex inc
  • Bausch and lomb inc
  • Cobalt laboratories inc
  • Copley pharmaceutical inc
  • Hi tech pharmacal co inc
  • Holopack international
  • Landela pharmaceutical
  • Nephron pharmaceuticals corp
  • Nephron corp
  • Novex pharma
  • Roxane laboratories inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Wockhardt eu operations (swiss) ag
  • Amneal pharmaceuticals
  • Mova pharmaceuticals corp
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals llc
  • Vistapharm inc
  • Mylan pharmaceuticals inc
  • Muro pharmaceutical inc
  • Dava pharmaceuticals inc
  • American therapeutics inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Ucb inc
  • Warner chilcott div warner lambert co
  • Breath ltd
  • Sepracor inc
  • Teva Pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
Aerosol, meteredRespiratory (inhalation)100 mcg
Aerosol, meteredOral90 ug/1
TabletOral2 mg/1
TabletOral4 mg/1
SolutionIntrabronchial.63 mg/3mL
SolutionIntrabronchial1.25 mg/3mL
SolutionIntrabronchial2.5 mg/3mL
SolutionOral2 mg/5mL
SolutionRespiratory (inhalation).75 mg/3mL
SolutionRespiratory (inhalation).83 mg/mL
SolutionRespiratory (inhalation)1.5 mg/3mL
SolutionRespiratory (inhalation)2.5 mg/.5mL
SolutionRespiratory (inhalation)2.5 mg/3mL
SolutionRespiratory (inhalation)5 mg/mL
SyrupOcclusive dressing technique2 mg/5mL
SyrupOral2 mg/5mL
TabletOral2.4 mg/1
Tablet, film coated, extended releaseOral4 mg/1
Tablet, film coated, extended releaseOral8 mg/1
Tablet, extended releaseOral4 mg/1
Tablet, extended releaseOral8 mg/1
TabletOral2 mg
TabletOral4 mg
Aerosol, meteredOral; Respiratory (inhalation)
Spray, meteredRespiratory (inhalation)
SolutionRespiratory (inhalation)
SolutionRespiratory (inhalation).31 mg/3mL
SolutionRespiratory (inhalation).63 mg/3mL
SolutionRespiratory (inhalation)1.25 mg/.5mL
SolutionRespiratory (inhalation)1.25 mg/3mL
Aerosol, meteredOral100 mcg
SolutionOral; Respiratory (inhalation)5 mg
SolutionRespiratory (inhalation)0.5 mg
SolutionOral0.4 mg
Powder, meteredRespiratory (inhalation)90 ug/1
SolutionRespiratory (inhalation)5 mg
LiquidRespiratory (inhalation)1 mg
LiquidRespiratory (inhalation)0.05 %
LiquidRespiratory (inhalation)0.1 %
LiquidRespiratory (inhalation)0.2 %
SolutionRespiratory (inhalation)1 mg
SolutionRespiratory (inhalation)2 mg
PowderRespiratory (inhalation)400 mcg
PowderRespiratory (inhalation)200 mcg
Aerosol, meteredRespiratory (inhalation)108 ug/1
Aerosol, meteredRespiratory (inhalation)90 ug/1
SolutionIntramuscular0.5 mg
SolutionIntravenous0.25 mg
SolutionIntravenous1 mg
LiquidIntramuscular.5 mg
LiquidIntravenous1 mg
LiquidIntravenous.25 mg
SolutionRespiratory (inhalation)2.5 mg
LiquidRespiratory (inhalation)1.25 mg
LiquidRespiratory (inhalation)2.5 mg
SolutionRespiratory (inhalation)1.25 mg
LiquidRespiratory (inhalation)5 mg
LiquidOral0.4 mg
LiquidOral.4 mg
CapsuleRespiratory (inhalation)200 mcg
CapsuleRespiratory (inhalation)400 mcg
Solution, concentrateRespiratory (inhalation)1.25 mg/.5mL
Aerosol, meteredOral45 ug/1
Prices
Unit descriptionCostUnit
Xopenex 0.63 mg/3 ml solution64.2USD ml
Proventil HFA 108 (90 Base)mcg/act Aerosol 6.7 gm Inhaler55.09USD inhaler
Xopenex HFA 45 mcg/act Aerosol 15 gm Inhaler53.84USD inhaler
AccuNeb 0.63 mg/3ml Neb. Solution 1 Box= 25 Vials53.14USD plastic
AccuNeb 1.25 mg/3ml Neb. Solution 1 Box= 25 Vials53.14USD plastic
ProAir HFA 108 (90 Base)mcg/act Aerosol 8.5 gm Inhaler45.99USD inhaler
Ventolin HFA 108 (90 Base)mcg/act Aerosol 18 gm Inhaler39.99USD inhaler
Proair hfa 90 mcg inhaler12.62USD g
Proventil hfa 90 mcg inhaler8.07USD g
Xopenex hfa 45 mcg inhaler6.12USD g
Xopenex 0.31 mg/3ml (1 Box = 24, 3ml Vials)4.87USD plastic
Xopenex 1.25 mg/3ml (1 Box = 24, 3ml Vials)4.87USD plastic
Xopenex 0.63 mg/3ml (1 Box = 24, 3ml Vials)4.71USD plastic
Xopenex 1.25 mg/3 ml solution2.96USD ml
Ventolin hfa 90 mcg inhaler2.01USD g
Xopenex 0.31 mg/3 ml solution1.56USD ml
Ventolin 5 mg/ml Solution1.13USD ml
Ventolin Nebules P.F. 2 mg/ml Unit Dose Solution0.88USD ml
Accuneb 0.63 mg/3 ml inh solution0.68USD ml
Accuneb 1.25 mg/3 ml inh solution0.68USD ml
Mylan-Salbutamol 5 mg/ml Solution0.62USD ml
Pms-Salbutamol 5 mg/ml Solution0.62USD ml
Ratio-Salbutamol 5 mg/ml Solution0.62USD ml
Sandoz Salbutamol 5 mg/ml Solution0.62USD ml
Mylan-Salbutamol Sterinebs P.F. 2 mg/ml Unit Dose Solution0.48USD ml
Pms-Salbutamol Polyneb 2 mg/ml Unit Dose Solution0.48USD ml
Ratio-Salbutamol Uni Dose P.F. 2 mg/ml Unit Dose Solution0.48USD ml
Ventolin Nebules P.F. 1 mg/ml Solution0.47USD ml
Mylan-Salbutamol Sterinebs P.F. 1 mg/ml Solution0.25USD ml
Pms-Salbutamol 1 mg/ml Solution0.25USD ml
Ratio-Salbutamol Sulf U.D.P.F. 1 mg/ml Solution0.25USD ml
Apo-Salvent 4 mg Tablet0.22USD tablet
Pms-Salbutamol 0.5 mg/ml Solution0.16USD ml
Ratio-Salbutamol Unit Dose P.F 0.5 mg/ml Solution0.16USD ml
Apo-Salvent 2 mg Tablet0.13USD tablet
Pms-Salbutamol 400 mcg/ml Liquid0.05USD ml
Ratio-Salbutamol Hfa 100 mcg/dose Metered Dose Aerosol0.04USD dose
Airomir Cfc-Free 100 mcg/dose Metered Dose Aerosol0.03USD dose
Apo-Salvent Cfc Free 100 mcg/dose Metered Dose Aerosol0.03USD dose
Ventolin Hfa 100 mcg/dose Metered Dose Aerosol0.03USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2125665 No2001-06-122012-12-04Canada
CA2125667 No2000-06-132012-12-04Canada
US5775321 No1995-07-072015-07-07Us
US5836299 No1995-11-172015-11-17Us
US5964416 No1996-10-042016-10-04Us
US6006745 No1996-12-282016-12-28Us
US6149054 No1996-12-192016-12-19Us
US6161724 Yes1998-07-162018-07-16Us
US6170717 Yes1998-06-232018-06-23Us
US6176442 No1996-10-042016-10-04Us
US6315173 Yes1998-06-232018-06-23Us
US6352684 No1992-11-282009-11-28Us
US6431168 Yes1998-12-082018-12-08Us
US6435372 Yes1998-07-162018-07-16Us
US6446627 No1997-12-182017-12-18Us
US6451289 No2001-03-212021-03-21Us
US6453795 No1996-12-052016-12-05Us
US6510969 Yes1998-06-232018-06-23Us
US6558651 Yes1997-06-192017-06-19Us
US6632842 No2001-12-282021-12-28Us
US6701917 No2001-06-232021-06-23Us
US6702997 No2001-12-282021-12-28Us
US6718972 No2001-06-232021-06-23Us
US6726124 No1996-10-042016-10-04Us
US6743413 Yes2001-12-012021-12-01Us
US6748947 No2001-06-232021-06-23Us
US6846413 No1998-08-282018-08-28Us
US6871646 No2001-06-232021-06-23Us
US6938796 Yes1998-07-162018-07-16Us
US6966467 Yes1998-06-232018-06-23Us
US6977042 No1998-08-282018-08-28Us
US6988496 No2000-02-232020-02-23Us
US6997349 Yes1998-07-162018-07-16Us
US7104470 No1996-10-042016-10-04Us
US7105152 No2003-09-122023-09-12Us
US7107986 Yes1998-12-062018-12-06Us
US7143908 Yes1998-07-162018-07-16Us
US7246615 No1996-05-312016-05-31Us
US7256310 No2004-10-082024-10-08Us
US7284474 No2004-08-262024-08-26Us
US7350676 Yes1999-02-242019-02-24Us
US7396341 No2006-10-102026-10-10Us
US7500444 Yes2006-08-262026-08-26Us
US7540282 No2003-05-062023-05-06Us
US7566445 No1997-06-042017-06-04Us
US7802568 No1999-02-262019-02-26Us
US7832351 Yes2003-12-192023-12-19Us
US7837235 No2008-03-132028-03-13Us
US7896264 No2005-05-262025-05-26Us
US7988001 No2001-08-042021-08-04Us
US8006690 No2001-06-232021-06-23Us
US8132712 No2008-09-072028-09-07Us
US8651103 No2008-03-262028-03-26Us
US8733341 No2009-12-162029-12-16Us
US8765153 No2003-12-082023-12-08Us
US8834849 No1997-06-042017-06-04Us
US8978966 No2012-01-132032-01-13Us
US9027967 No2007-03-312027-03-31Us
US9216260 No2011-06-282031-06-28Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)147-149Lunts, L.H.C. and Toon, P.; U.S. Patent 3,644,353; February 22,1972; assigned to Allen & Hanburys Ltd.
water solubility1.41E+004 mg/LYALKOWSKY,SH & HE,Y (2003)
logP1.4Not Available
logS-1.22ADME Research, USCD
pKa10.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.15 mg/mLALOGPS
logP0.44ALOGPS
logP0.34ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)10.12ChemAxon
pKa (Strongest Basic)9.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area72.72 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity67.87 m3·mol-1ChemAxon
Polarizability26.86 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9812
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7112
P-glycoprotein substrateSubstrate0.684
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.9673
Renal organic cation transporterNon-inhibitor0.8974
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7074
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9197
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9287
CYP450 3A4 inhibitorNon-inhibitor0.9343
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8834
Ames testNon AMES toxic0.8409
CarcinogenicityNon-carcinogens0.8863
BiodegradationNot ready biodegradable0.9734
Rat acute toxicity2.5275 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9564
hERG inhibition (predictor II)Non-inhibitor0.9288
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-00di-0090000000-afe3df5bdead805eacafView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-000i-0090000000-1d8b235dd1e02960dba1View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-00dr-0090000000-6fee6c25dfbf9c3a7c13View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-014i-0290000000-0d38029df88ee8018d9aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-00kf-0950000000-9572451e9f596ae94494View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0006-0900000000-05c59c5c9d63de269febView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-000i-0090000000-8ef6b84074e243e637bdView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-00dr-0090000000-e288fafc6755fa4abcbaView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-014i-0290000000-5569e08c145733118852View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0296-0940000000-f3558c829fecc8fea6f0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-0006-0900000000-9b7ad78396782fd2237dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , negativesplash10-00di-0090000000-19973e6238f364b40ec6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-00dl-0190000000-bec72774da692a955281View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-0002-0900000000-9d1b7a0e974ab4c5c2cfView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00di-0090000000-98cef35812448be3e2dbView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-006x-0090000000-182d7b602151e8ac7849View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-006t-0950000000-935c99cfc4690ce298f1View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0002-0900000000-064806e46a30b7dd760bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0002-0900000000-6acca58ec4a7b6892bb1View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzyl alcohols. These are organic compounds containing the phenylmethanol substructure.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzyl alcohols
Direct ParentBenzyl alcohols
Alternative ParentsAralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
SubstituentsBenzyl alcohol / Phenol / Aralkylamine / 1-hydroxy-2-unsubstituted benzenoid / Secondary alcohol / 1,2-aminoalcohol / Secondary amine / Secondary aliphatic amine / Hydrocarbon derivative / Alcohol
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptorsphenylethanolamines, phenols, secondary amino compound (CHEBI:2549 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Uniprot Name:
Beta-2 adrenergic receptor
Molecular Weight:
46458.32 Da
References
  1. Brichetto L, Milanese M, Song P, Patrone M, Crimi E, Rehder K, Brusasco V: Beclomethasone rapidly ablates allergen-induced beta 2-adrenoceptor pathway dysfunction in human isolated bronchi. Am J Physiol Lung Cell Mol Physiol. 2003 Jan;284(1):L133-9. Epub 2002 Aug 16. [PubMed:12388338 ]
  2. Chong LK, Suvarna K, Chess-Williams R, Peachell PT: Desensitization of beta2-adrenoceptor-mediated responses by short-acting beta2-adrenoceptor agonists in human lung mast cells. Br J Pharmacol. 2003 Feb;138(3):512-20. [PubMed:12569076 ]
  3. Yamanishi T, Chapple CR, Yasuda K, Yoshida K, Chess-Williams R: Role of beta-adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro. Neurourol Urodyn. 2003;22(4):338-42. [PubMed:12808710 ]
  4. Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P: Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004 Feb 6;485(1-3):227-34. [PubMed:14757145 ]
  5. Choudhry S, Ung N, Avila PC, Ziv E, Nazario S, Casal J, Torres A, Gorman JD, Salari K, Rodriguez-Santana JR, Toscano M, Sylvia JS, Alioto M, Castro RA, Salazar M, Gomez I, Fagan JK, Salas J, Clark S, Lilly C, Matallana H, Selman M, Chapela R, Sheppard D, Weiss ST, Ford JG, Boushey HA, Drazen JM, Rodriguez-Cintron W, Silverman EK, Burchard EG: Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med. 2005 Mar 15;171(6):563-70. Epub 2004 Nov 19. [PubMed:15557128 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Uniprot Name:
Beta-1 adrenergic receptor
Molecular Weight:
51322.1 Da
References
  1. Baker JG: The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005 Feb;144(3):317-22. [PubMed:15655528 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name:
ADRB3
Uniprot ID:
P13945
Uniprot Name:
Beta-3 adrenergic receptor
Molecular Weight:
43518.615 Da
References
  1. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug created on June 13, 2005 07:24 / Updated on July 25, 2017 17:54